BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mallio CA, Piervincenzi C, Gianolio E, Cirimele V, Papparella LG, Marano M, Quintiliani L, Aime S, Carducci F, Parizel PM, Quattrocchi CC. Absence of dentate nucleus resting-state functional connectivity changes in nonneurological patients with gadolinium-related hyperintensity on T 1 -weighted images: Functional Connectivity of T 1 Hyperintense DN. J Magn Reson Imaging 2019;50:445-55. [DOI: 10.1002/jmri.26669] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Splendiani A, Corridore A, Torlone S, Martino M, Barile A, Di Cesare E, Masciocchi C. Visible T1-hyperintensity of the dentate nucleus after multiple administrations of macrocyclic gadolinium-based contrast agents: yes or no? Insights Imaging 2019;10:82. [PMID: 31482392 DOI: 10.1186/s13244-019-0767-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Mallio CA, Rovira À, Parizel PM, Quattrocchi CC. Exposure to gadolinium and neurotoxicity: current status of preclinical and clinical studies. Neuroradiology 2020;62:925-34. [DOI: 10.1007/s00234-020-02434-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
3 Mallio CA, Quattrocchi CC, Rovira À, Parizel PM. Gadolinium Deposition Safety: Seeking the Patient's Perspective. AJNR Am J Neuroradiol 2020;41:944-6. [PMID: 32381539 DOI: 10.3174/ajnr.A6586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
4 Neal CH. Screening Breast MRI and Gadolinium Deposition: Cause for Concern? Journal of Breast Imaging 2022;4:10-8. [DOI: 10.1093/jbi/wbab074] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 McDonald JS, McDonald RJ. MR Imaging Safety Considerations of Gadolinium-Based Contrast Agents: Gadolinium Retention and Nephrogenic Systemic Fibrosis. Magn Reson Imaging Clin N Am 2020;28:497-507. [PMID: 33040991 DOI: 10.1016/j.mric.2020.06.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Mallio CA, Messina L, Parillo M, Lo Vullo G, Beomonte Zobel B, Parizel PM, Quattrocchi CC. Anterior pituitary gland T1 signal intensity is influenced by time delay after injection of gadodiamide. Sci Rep 2020;10:14967. [PMID: 32917963 DOI: 10.1038/s41598-020-71981-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kong N, Gao C, Xu M, Gao X. Changes in the anterior cingulate cortex in Crohn's disease: A neuroimaging perspective. Brain Behav 2021;11:e02003. [PMID: 33314765 DOI: 10.1002/brb3.2003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Sardanelli F, Cozzi A, Trimboli RM, Schiaffino S. Gadolinium Retention and Breast MRI Screening: More Harm Than Good? American Journal of Roentgenology 2020;214:324-7. [DOI: 10.2214/ajr.19.21988] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
9 Mallio CA, Parillo M, Zobel BB, Parizel PM, Quattrocchi CC. Effect of Exposure to Gadodiamide and Brain Irradiation on T 1 ‐Weighted Images and ADC Maps of the Dentate Nucleus. J Magn Reson Imaging 2020;52:1525-30. [DOI: 10.1002/jmri.27198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Yeung AWK. Structural and functional changes in the brain of patients with Crohn's disease: an activation likelihood estimation meta-analysis. Brain Imaging Behav 2021;15:807-18. [PMID: 32333318 DOI: 10.1007/s11682-020-00291-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Forslin Y, Martola J, Bergendal Å, Fredrikson S, Wiberg MK, Granberg T. Gadolinium Retention in the Brain: An MRI Relaxometry Study of Linear and Macrocyclic Gadolinium-Based Contrast Agents in Multiple Sclerosis. AJNR Am J Neuroradiol 2019;40:1265-73. [PMID: 31248867 DOI: 10.3174/ajnr.A6112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
12 Bäuerle T, Saake M, Uder M. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention. Rofo 2021;193:1010-8. [PMID: 33348385 DOI: 10.1055/a-1328-3177] [Reference Citation Analysis]
13 Cho SB, Lee AL, Chang HW, Kim KA, Yoo WJ, Yeom JA, Rho MH, Kim SJ, Lim YJ, Han M. Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients. J Magn Reson Imaging 2020;51:861-8. [PMID: 31663202 DOI: 10.1002/jmri.26940] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Mallio CA, Piervincenzi C, Carducci F, Quintiliani L, Parizel PM, Pantano P, Quattrocchi CC. Within-network brain connectivity in Crohn's disease patients with gadolinium deposition in the cerebellum. Neuroradiology 2020;62:833-41. [PMID: 32246178 DOI: 10.1007/s00234-020-02415-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Damme NM, Fernandez DP, Wang LM, Wu Q, Kirk RA, Towner RA, McNally JS, Hoffman JM, Morton KA. Analysis of retention of gadolinium by brain, bone, and blood following linear gadolinium-based contrast agent administration in rats with experimental sepsis. Magn Reson Med 2020;83:1930-9. [PMID: 31677194 DOI: 10.1002/mrm.28060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]